Biograil
PrivateLast Round
Early Funding
Nov 4, 2026
Total Funding Raised
$39.76M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Biograil operates in Healthcare & Life Sciences and is based in Roskilde. Its latest recorded funding round was an Early Funding round in November 2026.
Biograil is a therapeutic devices company that is developing a medical device designed to replace the standard injection system of medicines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biograil Comparables
Compare Biograil with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Intract Pharma | 86% | |
| Cyprumed GmbH | 86% | |
| i2O Therapeutics | 85% |
For institutional investors. Book with your work email.
Biograil Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Nov 4, 2026 | ||||
| Series B | Jul 1, 2025 | ||||
| Seed | Apr 5, 2024 | ||||
| Grant | Mar 14, 2022 | ||||
| Seed | Feb 17, 2022 | ||||
Seed | Jan 15, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biograil Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Grant |
| Verve Ventures | Seed, Early Funding, Series B |
| Sanner Ventures | Seed |
| Roquette Ventures | Seed |
| Evonik Venture Capital | Seed |
| MEGATREND INVEST A/S | Seed, Early Funding, Series B |
| High-Tech Gründerfonds | Seed, Early Funding, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 4, 2026
$22.45M raised from High-Tech Gründerfonds, MEGATREND INVEST, and Verve Ventures.
- Mar 2, 2026
Monthly visitors grew 195% MoM, reaching 1.2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 5, 2026
Biograil receives $22.4M in financing in Denmark on Nov 4th '26, with the round backed by Verve Ventures and Megatrend Invest and joined by HTGF Opportunity to support its oral drug-delivery device.
For institutional investors. Book with your work email.
Biograil Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biograil's valuation, stock price, and market status.
Is Biograil a public or private company?
Biograil is a private company.
What is the current stock price of Biograil?
Biograil is a private company, so its shares have no public market price. Caplight tracks Biograil's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biograil worth (valuation)?
Valuation information for Biograil is not publicly available.
Can I buy Biograil stock?
Biograil shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biograil's last funding round?
Biograil's most recent funding round was Early Funding on November 4, 2026.
Who are the main investors in Biograil?
Key investors in Biograil include Innovation Fund Denmark, Verve Ventures, MEGATREND INVEST A/S, High-Tech Gründerfonds.
Will Biograil IPO soon?
No public IPO plans have been announced for Biograil.
How can I track Biograil secondary market activity?
Caplight tracks bids, offers, and trades in Biograil's shares on secondary markets.